New and old antipsychotics versus clozapine in a monkey model: Adverse effects and antiamphetamine effects

Psychopharmacology

Volumn 144, Issue 3, 1999, Pages 189-197

  Peacock, Linda ^a   Gerlach, Jes ^a  

^a Sct Hans Hospital   (Denmark)

Author keywords

Adrenergic antagonist; Clozapine; Dopamine D1 antagonist Dopamine D2 antagonist; Extrapyramidal side effects; Monkey; Serotonin antagonist

Indexed keywords

8 CHLORO 5 (2,3 DIHYDROBENZOFURAN 7 YL) 2,3,4,5 TETRAHYDRO 3 METHYL 1H 3 BENZAZEPIN 7 OL; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BIPERIDEN; CLOZAPINE; DOD 647; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; MELPERONE; NEUROLEPTIC AGENT; NNC 220031; QUETIAPINE; SEROTONIN 2 ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; MALE; MONKEY; MYOCLONUS; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; TREMOR;

AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; CEBUS; CLOZAPINE; DEXTROAMPHETAMINE; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; DYSTONIA; FEMALE; MALE; MOTOR ACTIVITY; MOVEMENT DISORDERS;

EID: 0032983372     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050993     Document Type: Article

References (55)

1. 1 receptor antagonists. Eur J Pharmacol 219:45-52
2. Bartko JJ, Carpenter WT (1976) On the methods and theory of reliability. J Nerv Ment Dis 163:307-317
3. 1 antagonist SCH39166 in six cases of acute psychotic states. Psychopharmacology 21:323-327
4. Berman I, Zalma A, DuRand CJ, Green AI (1992) Clozapine-induced myoclonic jerks and drop attacks (letter). J Clin Psychiatry 53:329-330
5. Bjerkenstedt L, Harnryd C, Grimm V, Gullberg B, Sedvall G (1978) A double-blind comparison of melperone and thiothixene in psychotic women using a new rating scale, the CPRS. Arch Psychiatr Nervenkr 226:157-172
6. Borison RL, Arvantis LA, Miller BG and the US Seroquel Study Group (1996) ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 16:158-169
7. Brunello N, Masotto C, Steardo L, Markstein R, Racagni G (1995) New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 13:177-213
8. Casey DE (1989a) Clozapine: neuroleptic induced EPS and tardive dyskinesia. Psychopharmacology 99:47-53
9. Casey DE (1989b) Serotonergic aspects of acute extrapyramidal syndromes in nonhuman primates. Psychopharmacol Bull 25:457-459
10. Casey DE (1991) Extrapyramidal syndromes in nonhuman primates: typical and atypical neuroleptics. Psychopharmacol Bull 27:47-50
11. Casey DE (1993) Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates. Psychopharmacology 112:S55-S59
12. 1 (haloperidol) antagonists in a chronic double-blind placebo controlled trial in cebus monkeys. Psychopharmacology 121:289-293
13. 1 and serotonin mechanisms. In: Fog R, Gerlach J, Hemmingsen R (eds) Schizophrenia: an integrated view. Munksgaard, Copenhagen, pp 287-299
14. Casey DE (1996a) Extrapyramidal syndromes and new antipsychotic drugs: findings in patients and non-human primate models. Br J Psychiatry 168:32-39
15. Casey DE (1996b) "Seroquel" (quetiapine): preclinical and clinical findings of a new atypical antipsychotic. Exp Opin Invest Drugs 5:939-957
16. 1 receptor agonists in the treatment of schizophrenia. Psychopharmacol Bull 25:393-397
17. Csernansky JG, Newcomer JW, Jackson K, Lombrozo L, Faull KF, Zipursky R, Pfefferbaum A, Faustman WO (1994) Effects of raclopride treatment on plasma and CSF HVA: relationships with clinical improvement in male schizophrenics. Psychopharmacology 116:291-296
18. 1-DA receptor antagonist SCH39166 on positive and negative symptoms in schizophrenia. Psychopharmacology 121:317-322
19. 1 agonist quinpirole produce locomotor stimulation in dopamine depleted mice. Pharmacol Toxicol 67:123-131
20. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extra-pyramidal side effects. Arch Gen Psychiatry 49:538-544
21. Fitton A, Heel RC (1990) Clozapine: a review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs 40:722-747
22. Gelders YG (1989) Thymosthenic agents, a novel approach in the treatment of schizophrenia. Br J Pharmacol 155:33-36
23. Gerlach J, Hansen L (1993) Effect of chronic treatment with NNC 756, a new D-1 receptor antagonist, or raclopride, a D-2 receptor antagonist, in drug-naive Cebus monkeys: dystonia, dyskinesia and D-1/D-2 supersensitivity. J Psychopharmacol 7: 355-364
24. Haugen T (1967) Buronil, et nyt butyrofenonderivat ved akutte psykiatriske lidelser: en sammenligning med klorpromazin og klorprotiksen. Ugeskr Lœg 129:1194-1197
25. Hirsch SR (1994) Seroquel: an example of an atypical antipsycho tic drug. Neuropsychopharmacology 10:371S
26. Hirsch SR, Link CGG, Goldstein JM, Arvantis LA (1996) ICI 204,636: a new atypical antipsychotic drug. Br J Psychiatry 168:45-56
27. Jackson DM, Johansson C, Lindgren L-M, Bengtsson A (1994) Dopamine receptor antagonists block amphetamine and phencyclidine-induced motor stimulation in rats. Pharmacol Biochem Behav 48:465-471
28. Kane J, Honigfeld G, Singer J, Meltzer H and the Clozaril Collaborative Study Group (1988) Clozapine for the treatment of resistant schizophrenia: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796
29. 1 receptor antagonist, in the treatment of schizophrenia. Psychopharmacology 121:328-329
30. 1-dopamine receptor. Psychopharmacology 113:149-156
31. 1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology 121:309-316
32. 2 receptors. Psychopharmacology 112:S40-S54
33. Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J (1991) The effects of clozapine on tardive dyskinesia. Br J Psychiatry 158:503-510
34. Lindstrom LH (1988) The effect of long term treatment with clozapine in schizophrenia: a retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatr Scand 77:524-529
35. Liukkonen J, Koponen JH, Nousiainen U (1992) Clinical picture and long term course of epileptic seizures that occur during clozapine treatment. Psychiatry Res 44:101-112
36. 1 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment: extrapyramidal syndromes and dopaminergic supersensitivity. Psychopharmacology 112:389-397
37. Lyon M (1991) Animal models of mania and schizophrenia. In: Willner P (ed) Behavioral models in psychopharmacology: theoretical, industrial and clinical perspectives. Cambridge University Press, Cambridge, pp 253-306
38. 1-receptors. Eur Psychiatry 9: 52s
39. Meltzer HY (1989) Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99:S18-S27
40. Meltzer HY, Matsubara S, Lee J-C (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin 2 pKi values. J Pharmacol Exp Ther 1989 251:238-246
41. Migler BM, Warawa EJ, Malick JB (1993) Seroquel: behavioral effects in conventional and novel tests for atypical antipsy chotic drug. Psychopharmacology 112:299-307
42. Moore NA, Calligaro DO, Wong DT, Bymaster F, Tye NC (1993) The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 2:281-293
43. 1 agonist in the treatment of schizophrenia. In : Meltzer HY (ed) Novel antipsychotic drugs. Raven Press, New York, p 99
44. 1 receptor antagonists. Eur J Pharmacol 219:35-44
45. Nielsen EB, Andersen PH, Farde L, Karlsson P, Gronvald FC, Skrumsager BK (1992) Preclinical pharmacology and clinical effects in humans of dopamine D-1 receptor antagonism. Soc Neurosci Abstr 18:202
46. Nielsen EB, Hansen JB, Groønvald FC, Swedberg MDB, Scheideler M (1997) NNC 19-1228 and NNC 22-0031, novel neuroleptics with a "mesolimbic-selective" behavioral profile. Psychopharmacology 129:168-178
47. Ogren SO (1996) The behavioural pharmacology of typical and a typical antipsychotic drugs. In: Csernansky JG (ed) Antipsychotics. Springer, Berlin, pp 225-266
48. 1 receptor antagonist raclopride discriminates between dopamine-mediated motor functions. Psychopharmacology 90:287-294
49. 1 receptor agonists in Cebus apella monkeys previously treated with haloperidol. Eur J Pharmacol 237:329-340
50. 2 receptor agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment. Eur J Pharmacol 186:49-59
51. Peacock L, Solgaard T, Lublin H, Gerlach J (1996) Clozapine versus typical antipsychotics: a retro- and prospective study of extrapyramidal side effects. Psychopharmacology 124:188-196
52. Povlsen UJ, Noring U, Laursen AL, Korsgaard S, Gerlach J (1986) Effects of serotonergic and anticholinergic drugs in haloperidol-induced dystonia in cebus monkeys. Clin Neuropharmacol 9:84-90
53. Saller CF, Salama AI (1993) Seroquel: biochemical profile of a potential antipsychotic. Psychopharmacology 112:285-292
54. Schlusinger F, Kirkegaard Aa, Nielsen SK, Poulsen H, Vangtorp A, Gjeddebœk NF (1965) Klinisk forsøg med et nyt butyrofenonderivat, Buronil (FG 5111) ved svœr kronisk skizofreni: en sammenligning med klorpromazin. Nordisk Med 73:605-609
55. Wetzel H, Szegedi A, Hain C, Wiesner J, Schlegel S, Benkert O (1995) Seroquel (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and changes of neuroendocrinological and EEG parameters. Psychopharmacology 119:231-238